Known cardiac concerns
Cardiac disease, an abnormal electrocardiogram, long QT syndrome, prior arrhythmia, unexplained fainting, or concerning family history may be contraindications. These are not details to minimize during eligibility review.
Independent information resource
Is Ibogaine For Me? A Self-assessment
A calm starting point for people researching ibogaine: assess medical eligibility, medication risk, psychological readiness, and the standards that separate monitoring from marketing.
Ibogaine is not a self-directed wellness supplement. It is an investigational psychedelic compound with serious cardiac risks, uncertain benefit, and no FDA-approved therapeutic indication. The first question is not simply whether ibogaine could help, but whether its safety profile makes sense for your circumstances.
- 12-lead ECGBefore any dosing discussion
- QTc reviewCardiac eligibility is not optional
- 24/7 monitoringDuring a flood dose and recovery
- Aftercare planIntegration begins before travel
Start with the risk question
Medical contraindications and health screening
A useful self-assessment is a prompt to pause, not a way to clear yourself. Ibogaine is an indole alkaloid extracted from the root bark of the West African shrub Tabernanthe iboga. Although iboga has cultural and historical contexts, a treatment decision requires formal medical screening and independent clinical judgment.
Neurological history
A history of traumatic brain injury, stroke, aneurysm, or active seizure disorders typically appears among exclusion criteria because ibogaine can add neurological risk during an already demanding experience.
Current medical stability
Medical screening should include current illness, blood pressure, vital signs, hepatic function, medication use, hydration, and the practical ability to receive medical supervision before, during, and after dosing.
“Natural” does not mean predictable, and it does not remove the need for exclusion criteria, a complete history, or an emergency protocol.
Programs describe their own candidate criteria differently, but a detailed candidate screening framework illustrates why an honest health history belongs before travel plans. A separate eligibility questionnaire can help identify questions to bring to a clinician, but it cannot replace medical screening.
Cardiac gate
Cardiac risks and QT prolongation
Ibogaine delays cardiac ventricular repolarization by blocking cardiac hERG potassium channels. This hERG channel effect can induce QT prolongation and lengthen the QTc interval, creating conditions in which a dangerous arrhythmia may occur.
A baseline QTc interval exceeding 450 milliseconds in men or 470 milliseconds in women is a standard medical contraindication to treatment. Long QT syndrome, a previous arrhythmia, or pre-existing cardiovascular disease should move the conversation toward caution and specialist evaluation, not a workaround.
A responsible protocol requires a 12-lead electrocardiogram and comprehensive metabolic panels before dosing. That means an ECG is reviewed alongside an electrolyte panel that verifies serum potassium and magnesium levels. Low potassium or low magnesium can worsen QT prolongation; normal values should be confirmed rather than assumed.
Fatalities associated with ibogaine have predominantly involved unmonitored cardiac arrhythmia such as torsades de pointes or pre-existing cardiovascular disease. The FDA’s drug development process explains why investigational treatments need structured protocols rather than casual assurances.
Ask whether a treatment center repeats an ECG when indicated, reviews the QTc interval after medication changes, monitors blood pressure and vital signs, and can respond to torsades de pointes. A description of ibogaine treatment risk assessment is useful only if it translates into documented screening, not just a claim of safety.
Medication and substance review
Substance use disorders and opioid detox
People often research ibogaine because opioid use disorder, withdrawal symptoms, or repeated relapse has made other paths feel insufficient. That urgency is understandable. It also makes timing, detoxification, and medication review especially consequential.
What people hope to interrupt
Ibogaine may alter subjective withdrawal symptoms and reward-related processes during a brief but intense psychedelic experience. In the liver, ibogaine is converted through CYP2D6 into noribogaine, its primary active metabolite. Noribogaine has longer-lasting reuptake effects involving serotonin and dopamine.
This biology is part of why ibogaine interests people researching addiction treatment. It is not proof that it safely resolves opioid use disorder, depression, PTSD, or trauma. Recovery still requires a plan that can hold up after detoxification.
What must be stabilized first
Patients taking long-acting synthetic opioids such as methadone or buprenorphine must transition to short-acting opioids for three to six weeks before ibogaine administration. A rushed methadone or buprenorphine change can bring severe withdrawal symptoms and instability.
Fentanyl adds uncertainty because exposure and clearance can be difficult to predict. Anyone considering ibogaine after fentanyl, methadone, buprenorphine, or other short-acting opioids should seek individualized medical advice; no online timeline can establish eligibility.
Some treatment explanations describe ibogaine as an interruption in dependence, while others focus on opioid detox. An overview of ibogaine addiction treatment and therapy may clarify the questions people ask, but the decision belongs within medical supervision and harm reduction. A guide to who may benefit from ibogaine treatment should similarly be read as context, not a personal clearance.
Mental health screen
Psychiatric evaluation and mental health criteria
Mental health is not a simple yes-or-no gate. Depression, PTSD, trauma, grief, and chronic stress may be part of why someone is considering ibogaine. But psychological readiness and present stability must be assessed separately from the hope of relief.
Ibogaine is medically contraindicated for people with a personal or first-degree family history of schizophrenia, psychosis, or bipolar I disorder due to the risk of prolonged mania or psychotic episodes. Bipolar disorder, previous psychosis, acute suicidality, or a recent psychiatric crisis require particular caution.
A thorough psychiatric evaluation should include psychiatric medication history, current depression symptoms, PTSD symptoms, sleep, substance use, trauma history, social support, and whether the person can participate in psychotherapy and aftercare. A screening discussion from a consideration of whether ibogaine is right for you does not replace that work.
Ibogaine can produce a visionary or oneiric state generally lasting six to 12 hours, followed by a processing period marked by substantial ataxia. A person must be able to consent freely, remain safe with assistance, and understand that the experience may bring difficult material to the surface.
Interaction map
Medication interactions to consider
Medication review is central to safety. Ibogaine and noribogaine involve CYP2D6 metabolism, and concurrent substances that use the cytochrome P450 2D6 pathway can alter clearance rates and increase ibogaine plasma toxicity.
- List everything. Include prescriptions, over-the-counter products, supplements, recent substances, antidepressants, SSRIs, SNRIs, MAOIs, stimulants, and pain medicines. Do not omit a medication because you plan to stop it later.
- Check timing medically. Concomitant ibogaine with serotonergic medications such as SSRIs, SNRIs, or MAOIs carries a life-threatening risk of serotonin syndrome. Tapering antidepressants or changing medication without prescriber support can also be unsafe.
- Review metabolism and liver status. Liver function tests and hepatic function matter because CYP2D6 contributes to the conversion of ibogaine into noribogaine. A medication interaction can alter metabolism even when a person feels physically well.
- Repeat the cardiac check. An ECG, QTc interval review, potassium, magnesium, and an electrolyte panel should be current after any relevant medication or detoxification change.
More detail about the days before treatment appears in a 30-day ibogaine preparation outline, but preparation should never become unsupervised medication management. For basic context, the CYP2D6 reference overview explains why genetic and medication-related variation can matter to drug metabolism.
Facility standard
Evaluating safety standards at treatment centers
Location is not a safety credential. People researching ibogaine may encounter options in Mexico or Costa Rica, but a treatment center should be judged by its clinical systems, not destination imagery, testimonials, or promises about sobriety.
Continuous monitoring
Medical supervision during a flood dose requires continuous cardiac telemetry, pulse oximetry, repeated vital signs, and documented blood pressure monitoring. Ask who watches the ECG and who escalates a change.
Emergency capability
Clinical staff should be ACLS certified, with an emergency protocol, supplemental oxygen, intravenous electrolytes, and a defibrillator or AED available on premise. “Nearby hospital” is not the same as immediate response.
Transparent exclusion criteria
A credible treatment center can clearly explain contraindications, ECG thresholds, medication exclusions, medical screening, and when it will decline a person. Evasion is not a reassuring safety profile.
Ask directly how clinical staff handle QT prolongation, arrhythmia, torsades de pointes, low potassium, low magnesium, and blood pressure changes. A clinic profile describing a new-path program may offer examples of questions, while a reflection on whether ibogaine is for you should not substitute for direct confirmation of emergency resources.
About this resource: our independent approach to ibogaine questions is built for people researching evidence, safety, legality, and practical decisions. We do not offer treatment, and our practical research guides are designed to help readers prepare better questions rather than make a clinical recommendation.
Continuity after dosing
Aftercare planning and integration support
Ibogaine does not remove the need for recovery work. The idea that ibogaine may support neuroplasticity, including through GDNF-related activity in the brain, is not a substitute for integration, stable housing, therapy, and a plan for triggers, relationships, and relapse risk.
Before a decision
- Define what support is available after detoxification.
- Identify psychotherapy, peer support, and medical follow-up.
- Plan for sleep, nutrition, transport, and sober support.
- Consider whether recovery goals can be maintained after travel.
After a session
- Expect fatigue, ataxia, and a need for practical support.
- Allow space to process the oneiric state without treating it as a diagnosis.
- Use integration to connect insight with daily choices.
- Keep harm reduction and medical care available if withdrawal symptoms return.
An overview of ibogaine preparation and recovery considerations can help people name the logistical gaps they need to address. The National Institute on Drug Abuse’s overview of treatment for substance use disorders also underscores that addiction treatment is usually ongoing care, not a single event.
Questions to take forward
Self-assessment checklist for ibogaine treatment
This self-assessment is not a diagnosis or eligibility determination. It is a way to notice the information that must be complete before anyone considers ibogaine, iboga root bark products, or a flood dose.
What medical conditions disqualify someone from taking ibogaine?
Common contraindications include a prolonged QTc interval, long QT syndrome, cardiovascular disease, prior arrhythmia, serious electrolyte imbalance, active seizure disorders, traumatic brain injury, stroke, aneurysm, and concerning psychiatric history. Exclusion criteria also commonly include schizophrenia, psychosis, bipolar I disorder, and instability requiring urgent care. A clinician must determine medical eligibility through medical screening.
How does ibogaine help interrupt substance dependence and withdrawal?
Ibogaine and noribogaine may affect several receptor and neurotransmitter systems, and some people report changes in withdrawal symptoms during opioid detoxification. The proposed effects on reward circuitry, serotonin, dopamine, GDNF, and neuroplasticity remain an active research topic. They do not guarantee recovery from opioid use disorder, fentanyl exposure, depression, PTSD, or trauma.
What cardiac tests are mandatory before ibogaine therapy?
A 12-lead electrocardiogram, ECG review, QTc interval assessment, comprehensive metabolic testing, and an electrolyte panel that includes potassium and magnesium are fundamental. Programs should repeat relevant assessment after detoxification or medication changes, then maintain telemetry, pulse oximetry, vital signs, and cardiac oversight during the flood dose.
Can people with psychiatric conditions safely undergo ibogaine treatment?
Mental health history requires individualized clinical assessment. Depression and PTSD do not answer the eligibility question by themselves, but schizophrenia, psychosis, bipolar disorder, bipolar I disorder, current mania, and acute instability are major concerns. Psychological readiness, informed consent, psychotherapy, and aftercare integration are necessary safeguards, not optional extras.
What should a patient look for in a medically licensed ibogaine clinic?
Look for clear medical screening, transparent contraindications, an ECG process, QT prolongation policies, liver function tests, medication review, continuous cardiac monitoring, ACLS certified clinical staff, pulse oximetry, an emergency protocol, a defibrillator, oxygen, intravenous electrolytes, and a real aftercare plan. Never treat a polished website, a social-media post about being an ibogaine candidate, or a claim of medical supervision as proof that these systems exist.
A recent clinical review of ibogaine research is a reminder that research questions and treatment marketing are not the same thing. Keep your self-assessment grounded in evidence, transparent uncertainty, and the possibility that a safer evidence-based route should come first.
A safer next step
Bring a complete question set, not a predetermined answer.
If your self-assessment raises cardiac, psychiatric, medication, detoxification, or aftercare concerns, pause. Discuss them with qualified medical professionals and do not pursue underground treatment. Ibogaine remains investigational, and safety must be the starting condition.
Review risk and monitoring questionsFor further context, see ibogainehowlongdoesitlast.com.